SG Americas Securities
CMPX icon

SG Americas Securities’s Compass Therapeutics CMPX Stock Holding History

SG Americas Securities’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
76,355
+28,685
+60% +$84.7K ﹤0.01% 2878
2026
Q1 		$252K Sell
47,670
-58,863
-55% -$340K ﹤0.01% 2537
2025
Q4 		$572K Sell
106,533
-42,780
-29% -$198K ﹤0.01% 2412
2025
Q3 		$523K Sell
149,313
-223,368
-60% -$706K ﹤0.01% 2073
2025
Q2 		$969K Sell
372,681
-568,103
-60% -$1.17M ﹤0.01% 1202
2025
Q1 		$1.79M Buy
940,784
+545,767
+138% +$1.45M 0.01% 839
2024
Q4 		$573K Buy
395,017
+356,352
+922% +$592K ﹤0.01% 1207
2024
Q3 		$71K Buy
38,665
+5,515
+17% +$6.87K ﹤0.01% 3166
2024
Q2 		$33K Buy
33,150
+4,409
+15% +$6.44K ﹤0.01% 2733
2024
Q1 		$57K Sell
28,741
-18,883
-40% -$32.6K ﹤0.01% 2722
2023
Q4 		$74K Buy
47,624
+8,817
+23% +$15.3K ﹤0.01% 2845
2023
Q3 		$76K Buy
+38,807
New +$96K ﹤0.01% 2859

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SG Americas Securities's CMPX Position: Q2 2026 in Review

SG Americas Securities increased its Compass Therapeutics (CMPX) stake by 60% in Q2 2026, buying an estimated $84.7K and bringing the position to 76,355 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

SG Americas Securities first reported a position in CMPX in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.79M in Q1 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • SG Americas Securities held 76,355 shares of Compass Therapeutics worth $167K as of Q2 2026.
  • SG Americas Securities bought 28,685 Compass Therapeutics shares in Q2 2026, an estimated $84.7K.
  • Compass Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2878 holding.
  • SG Americas Securities first reported a position in Compass Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • SG Americas Securities's Compass Therapeutics position peaked at $1.79M in Q1 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.